PNCK

Summary

PNCK (pregnancy up-regulated nonubiquitous CaM kinase, HGNC:13415) is a protein-coding gene on chromosome Xq28, encoding Calcium/calmodulin-dependent protein kinase type 1B (Q6P2M8). Calcium/calmodulin-dependent protein kinase belonging to a proposed calcium-triggered signaling cascade.

PNCK is a member of the calcium/calmodulin-dependent protein kinase family of protein serine/threonine kinases (see CAMK1; MIM 604998) (Gardner et al., 2000 [PubMed 10673339]).

Source: NCBI Gene 139728 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 63 total
• Druggable target: yes
• MANE Select transcript: NM_001366977

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13415
Approved symbol	PNCK
Name	pregnancy up-regulated nonubiquitous CaM kinase
Location	Xq28
Locus type	gene with protein product
Status	Approved
Aliases	MGC45419, CaMK1b
Ensembl gene	ENSG00000130822
Ensembl biotype	protein_coding
OMIM	300680
Entrez	139728

Gene structure

Transcript identifiers

Ensembl transcripts: 51 — 33 protein_coding, 10 retained_intron, 6 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000340888, ENST00000370142, ENST00000370145, ENST00000370150, ENST00000411968, ENST00000418241, ENST00000419804, ENST00000422811, ENST00000423545, ENST00000425526, ENST00000433470, ENST00000434652, ENST00000438984, ENST00000439087, ENST00000447676, ENST00000458354, ENST00000460106, ENST00000462280, ENST00000463548, ENST00000465303, ENST00000466074, ENST00000466638, ENST00000466662, ENST00000472324, ENST00000473680, ENST00000473831, ENST00000475172, ENST00000480693, ENST00000484705, ENST00000488168, ENST00000488994, ENST00000489536, ENST00000870375, ENST00000870376, ENST00000870377, ENST00000870378, ENST00000870379, ENST00000870380, ENST00000922477, ENST00000922478, ENST00000922479, ENST00000922480, ENST00000955616, ENST00000955617, ENST00000955618, ENST00000955619, ENST00000955620, ENST00000955621, ENST00000955622, ENST00000955623, ENST00000955624

RefSeq mRNA: 8 — MANE Select: NM_001366977 NM_001039582, NM_001135740, NM_001366975, NM_001366976, NM_001366977, NM_001366978, NM_001366979, NM_001366980

CCDS: CCDS35503, CCDS48189, CCDS94698

Canonical transcript exons

ENST00000340888 — 12 exons

Exon	Start	End
ENSE00001451966	153673780	153673813
ENSE00003462640	153671078	153671190
ENSE00003477012	153670918	153670996
ENSE00003505261	153673009	153673078
ENSE00003563141	153671880	153672018
ENSE00003571548	153670450	153670594
ENSE00003612816	153671549	153671672
ENSE00003620909	153671285	153671360
ENSE00003653614	153670744	153670831
ENSE00003660164	153672126	153672200
ENSE00003692536	153672566	153672697
ENSE00003900260	153669733	153670130

Expression profiles

Bgee: expression breadth ubiquitous, 175 present calls, max score 96.24.

FANTOM5 (CAGE): breadth broad, TPM avg 1.9891 / max 97.3695, expressed in 273 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
200894	1.1009	229
200891	0.2575	77
200895	0.1664	74
200897	0.1520	49
200896	0.1424	71
200893	0.1066	69
200892	0.0634	42

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right frontal lobe	UBERON:0002810	96.24	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.20	gold quality
nucleus accumbens	UBERON:0001882	96.16	gold quality
anterior cingulate cortex	UBERON:0009835	95.84	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.68	gold quality
amygdala	UBERON:0001876	94.36	gold quality
caudate nucleus	UBERON:0001873	93.85	gold quality
putamen	UBERON:0001874	93.74	gold quality
prefrontal cortex	UBERON:0000451	93.67	gold quality
hypothalamus	UBERON:0001898	92.94	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	92.72	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	92.64	gold quality
frontal cortex	UBERON:0001870	92.42	gold quality
lower esophagus	UBERON:0013473	92.40	gold quality
lower esophagus muscularis layer	UBERON:0035833	92.40	gold quality
neocortex	UBERON:0001950	92.22	gold quality
cerebral cortex	UBERON:0000956	90.85	gold quality
Ammon’s horn	UBERON:0001954	90.03	gold quality
temporal lobe	UBERON:0001871	89.70	gold quality
forebrain	UBERON:0001890	89.18	gold quality
brain	UBERON:0000955	88.16	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.32	gold quality
popliteal artery	UBERON:0002250	87.22	gold quality
tibial artery	UBERON:0007610	87.21	gold quality
cerebellar hemisphere	UBERON:0002245	86.63	gold quality
saphenous vein	UBERON:0007318	86.58	gold quality
smooth muscle tissue	UBERON:0001135	86.54	gold quality
cerebellar cortex	UBERON:0002129	86.53	gold quality
superior frontal gyrus	UBERON:0002661	86.00	gold quality
mucosa of stomach	UBERON:0001199	85.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.99

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 5)

• Pnck induces ligand-independent EGFR degradation, and it may represent an attractive therapeutic target in EGFR-regulated oncogenesis. (PMID:18562482)
• Pnck induces epidermal growth factor receptor degradation, most likely through perturbation of Hsp90 chaperone activity due to Hsp90 phosphorylation. Epidermal growth factor receptor degradation is coupled to proteasomal degradation of Pnck. (PMID:21325639)
• the relationship between PNCK and prognosis in clear cell renal cell carcinoma (PMID:23634203)
• Pnck may be a marker of Trastuzumab resistance and possibly a therapeutic target in breast cancer. (PMID:25773930)
• Expression of Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (PNCK) in Hepatocellular Carcinoma. (PMID:33099476)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Pnck	ENSMUSG00000002012
rattus_norvegicus	Pnck	ENSRNOG00000058317

Paralogs (22): CAMKK1 (ENSG00000004660), CAMK1G (ENSG00000008118), CAMK2B (ENSG00000058404), CAMK2A (ENSG00000070808), MYLK2 (ENSG00000101306), CAMKK2 (ENSG00000110931), STK11 (ENSG00000118046), STK33 (ENSG00000130413), DCLK1 (ENSG00000133083), CAMK1 (ENSG00000134072), MYLK3 (ENSG00000140795), CAMK2D (ENSG00000145349), MYLK4 (ENSG00000145949), PSKH2 (ENSG00000147613), CAMK2G (ENSG00000148660), PHKG2 (ENSG00000156873), PSKH1 (ENSG00000159792), DCLK3 (ENSG00000163673), CAMKV (ENSG00000164076), PHKG1 (ENSG00000164776), DCLK2 (ENSG00000170390), CAMK1D (ENSG00000183049)

Protein

Protein identifiers

Calcium/calmodulin-dependent protein kinase type 1B — Q6P2M8 (reviewed: Q6P2M8)

Alternative names: CaM kinase I beta, Pregnancy up-regulated non-ubiquitously-expressed CaM kinase

All UniProt accessions (9): Q6P2M8, C9J2B9, C9J8P0, C9JB09, C9JEC5, C9JJ18, F8WAQ5, F8WBU7, H7BZQ5

UniProt curated annotations — full annotation on UniProt →

Function. Calcium/calmodulin-dependent protein kinase belonging to a proposed calcium-triggered signaling cascade. In vitro phosphorylates CREB1 and SYN1/synapsin I. Phosphorylates and activates CAMK1.

Subcellular location. Cytoplasm. Nucleus.

Post-translational modifications. Phosphorylated by CAMKK1.

Activity regulation. Activated by Ca(2+)/calmodulin.

Similarity. Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CaMK subfamily.

Isoforms (5)

UniProt ID	Names	Canonical?
Q6P2M8-1	1	yes
Q6P2M8-2	2
Q6P2M8-3	3
Q6P2M8-5	4
Q6P2M8-6	5

RefSeq proteins (8): NP_001034671, NP_001129212, NP_001353904, NP_001353905, NP_001353906, NP_001353907, NP_001353908, NP_001353909 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR042696	CaMKI_beta_STKc	Domain

Pfam: PF00069

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (13 total): splice variant 4, region of interest 2, binding site 2, chain 1, domain 1, sequence variant 1, sequence conflict 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6P2M8-F1	82.40	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 136 (proton acceptor)

Ligand- & substrate-binding residues (2): 21–29; 44

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 73 (showing top): AREB6_03, CAGGTCC_MIR492, CATRRAGC_UNKNOWN, DURCHDEWALD_SKIN_CARCINOGENESIS_DN, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN, GOMF_PROTEIN_KINASE_ACTIVITY, GOMF_KINASE_ACTIVITY, GOMF_CALCIUM_CALMODULIN_DEPENDENT_PROTEIN_KINASE_ACTIVITY, YOSHIMURA_MAPK8_TARGETS_UP, GOMF_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY, GOMF_ADENYL_NUCLEOTIDE_BINDING, GOMF_TRANSFERASE_ACTIVITY_TRANSFERRING_PHOSPHORUS_CONTAINING_GROUPS, chrXq28, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B, BAKKER_FOXO3_TARGETS_DN

GO Biological Process (2): signal transduction (GO:0007165), protein phosphorylation (GO:0006468)

GO Molecular Function (9): calcium/calmodulin-dependent protein kinase activity (GO:0004683), calmodulin binding (GO:0005516), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein kinase activity	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
phosphorylation	1
protein modification process	1
protein serine/threonine kinase activity	1
protein binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1714 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PNCK	IRAK1	P51617	533
PNCK	NOMO3	P69849	507
PNCK	NOMO2	Q5JPE7	507
PNCK	NOMO1	P78421	505
PNCK	FGF3	P11487	496
PNCK	HAUS7	Q99871	463
PNCK	CALM1	P02593	424
PNCK	CALML3	P27482	423
PNCK	CALML5	Q9NZT1	423
PNCK	CAMK2A	Q9UQM7	422
PNCK	KRT3	P12035	408
PNCK	TEX28	O15482	401
PNCK	DENR	O43583	397
PNCK	CALML6	Q8TD86	386
PNCK	CALML4	Q96GE6	386

IntAct

3 interactions, top by confidence:

A	B	Type	Score
PNCK	PTPN11	psi-mi:“MI:0915”(physical association)	0.370
EPHA4	PNCK	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (1): PNCK (Two-hybrid)

ESM2 similar proteins: A8X6H4, O70150, O75582, P10665, P11275, P11798, P18652, P18653, P18654, P28583, P51812, Q13557, Q14012, Q15349, Q2HJF7, Q38869, Q38871, Q38872, Q39016, Q42396, Q54CY9, Q54SJ5, Q5F3L1, Q5R4K3, Q5RCC4, Q5ZKI0, Q63450, Q63531, Q6DEH3, Q6GLS4, Q6P2M8, Q6PFQ0, Q6PHZ2, Q7TPS0, Q869W6, Q8BW96, Q8IU85, Q8RWL2, Q8VDF3, Q91YS8

Diamond homologs: A0A2I0BVG8, A0A509AFG4, A0A509AHB6, A0A509ALV6, A0A509AQE6, A0A5K1K8H0, A2XFF4, A8X6H4, B8BBT7, E9PT87, F4JBP3, O15865, O22932, O61267, O70150, O80673, P05986, P08414, P13234, P18654, P22216, P22517, P25323, P27466, P28582, P34101, P40376, P51812, P53681, P53684, P62343, P62344, P62345, P92958, P93759, Q00771, Q09170, Q0D715, Q0VD22, Q10KY3

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
PNCK	up-regulates	EIF4G3	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

63 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	31
Likely benign	5
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1808 predictions. Top by Δscore:

Variant	Effect	Δscore
X:153670740:TGA:T	donor_loss	1.0000
X:153670741:GACC:G	donor_loss	1.0000
X:153670830:TC:T	acceptor_gain	1.0000
X:153670830:TCC:T	acceptor_loss	1.0000
X:153670831:CC:C	acceptor_gain	1.0000
X:153670831:CCT:C	acceptor_loss	1.0000
X:153670832:C:CC	acceptor_gain	1.0000
X:153670832:CTGG:C	acceptor_loss	1.0000
X:153670914:TCA:T	donor_loss	1.0000
X:153670915:CACCA:C	donor_loss	1.0000
X:153670916:A:AC	donor_gain	1.0000
X:153670916:ACCA:A	donor_loss	1.0000
X:153670917:C:A	donor_loss	1.0000
X:153670917:C:CC	donor_gain	1.0000
X:153670917:CCAAA:C	donor_gain	1.0000
X:153670992:TTTGG:T	acceptor_gain	1.0000
X:153670993:TTGG:T	acceptor_gain	1.0000
X:153670994:TGG:T	acceptor_gain	1.0000
X:153670995:GG:G	acceptor_gain	1.0000
X:153670997:C:CC	acceptor_gain	1.0000
X:153670998:T:C	acceptor_loss	1.0000
X:153671542:C:A	donor_gain	1.0000
X:153671582:G:C	donor_gain	1.0000
X:153671592:AG:A	donor_gain	1.0000
X:153672119:T:TA	donor_gain	1.0000
X:153672124:A:AC	donor_gain	1.0000
X:153672125:C:CC	donor_gain	1.0000
X:153672125:CAGTT:C	donor_gain	1.0000
X:153672129:T:TA	donor_gain	1.0000
X:153672561:CGCA:C	donor_loss	1.0000

AlphaMissense

2239 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:153671313:A:G	W196R	1.000
X:153671313:A:T	W196R	1.000
X:153671616:G:C	D157E	1.000
X:153671616:G:T	D157E	1.000
X:153671617:T:A	D157V	1.000
X:153671617:T:G	D157A	1.000
X:153671887:T:A	D136V	1.000
X:153671887:T:G	D136A	1.000
X:153672634:C:A	K44N	1.000
X:153672634:C:G	K44N	1.000
X:153670951:C:A	R258M	0.999
X:153671099:A:G	W236R	0.999
X:153671099:A:T	W236R	0.999
X:153671169:G:C	F212L	0.999
X:153671169:G:T	F212L	0.999
X:153671171:A:G	F212L	0.999
X:153671173:G:T	P211H	0.999
X:153671303:C:T	G199D	0.999
X:153671304:C:G	G199R	0.999
X:153671311:C:A	W196C	0.999
X:153671311:C:G	W196C	0.999
X:153671566:C:T	G174E	0.999
X:153671611:C:T	G159E	0.999
X:153671617:T:C	D157G	0.999
X:153671618:C:G	D157H	0.999
X:153671662:A:G	L142P	0.999
X:153671664:G:C	N141K	0.999
X:153671664:G:T	N141K	0.999
X:153671666:T:C	N141D	0.999
X:153671880:C:A	K138N	0.999

dbSNP variants (sampled 300 via entrez): RS1000329399 (X:153670074 C>T), RS1000445471 (X:153669894 G>T), RS1000513717 (X:153678393 A>C), RS1001304544 (X:153683400 A>C,G), RS1002218138 (X:153676224 A>G), RS1002316609 (X:153685413 C>T), RS1002592102 (X:153676744 A>T), RS1002814103 (X:153672500 A>C), RS1002976486 (X:153681346 G>A), RS1003255895 (X:153672048 G>A,T), RS1004507513 (X:153675075 G>T), RS1004733690 (X:153683972 T>C), RS1005106287 (X:153684427 C>T), RS1005287908 (X:153670486 G>A), RS1005391419 (X:153679788 T>C)

Disease associations

OMIM: gene MIM:300680 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3627592 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CAMK1 family

ChEMBL bioactivities

11 potent at pChembl≥5 of 11 total, top 11 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.52	IC50	3	nM	CHEMBL4635883
8.42	IC50	3.78	nM	STAUROSPORINE
8.30	IC50	4.99	nM	STAUROSPORINE
8.21	IC50	6.12	nM	STAUROSPORINE
7.96	IC50	11	nM	CHEMBL4640712
6.08	IC50	830	nM	CHEMBL5093741
6.00	IC50	1000	nM	TP-030-1
6.00	IC50	1000	nM	TP-030-2
6.00	IC50	1000	nM	TP-030n
5.52	IC50	3000	nM	CHEMBL4795714
5.00	Kd	1e+04	nM	CHEMBL4848254

PubChem BioAssay actives

8 with measured affinity, of 70 total; 6 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(3S)-3-aminopiperidin-1-yl]-4-[[2,6-di(propan-2-yl)-4-pyridinyl]amino]pyrimidine-5-carboxamide	1668857: Inhibition of human CAMK1B using KKALRRQETVDAL as substrate in presence of [gamma-33P]-ATP by hotspot kinase assay	ic50	0.0030	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1715431: Inhibition of human CAMK1B using KKALRRQETVDAL as substrate by [gamma-33P]-ATP assay	ic50	0.0038	uM
2-[(3S)-3-aminopiperidin-1-yl]-4-[3,5-bis(2-cyanopropan-2-yl)anilino]pyrimidine-5-carboxamide	1668857: Inhibition of human CAMK1B using KKALRRQETVDAL as substrate in presence of [gamma-33P]-ATP by hotspot kinase assay	ic50	0.0110	uM
10,14-dimethyl-9-oxo-3-(trifluoromethyl)-4,5,10,13,14,19,21-heptazapentacyclo[15.5.2.12,5.012,16.020,23]pentacosa-1(22),2(25),3,12,15,17(24),18,20(23)-octaene-15-carbonitrile	1823455: Inhibition of CAMK1B (unknown origin) at 1 uM by kinome scan method	ic50	0.8300	uM
1-pentyl-4-(2-phenylmethoxyphenyl)imidazol-2-amine;hydrochloride	1734145: Inhibition of wild-type human CAMK1beta using KKALRRQETVDAL peptide as substrate in presence of Ca2+ calmodulin and [gamma-33P]-ATP by radiometric hotspot kinase assay	ic50	3.0000	uM
N,N-dimethyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine	1752106: Binding affinity to wild-type human partial length CAMK1B (W9 to A311 residues) expressed in mammalian expression system measured after 1 hr by competitive binding assay	kd	10.0000	uM

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases methylation, affects cotreatment, decreases expression	3
trichostatin A	affects cotreatment, decreases expression	2
Air Pollutants	increases abundance, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Smoke	decreases expression, increases abundance, increases expression	2
methylmercuric chloride	decreases expression	1
bisphenol A	affects expression	1
sulforaphane	increases expression	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
nutlin 3	increases expression, affects cotreatment	1
dorsomorphin	decreases expression, affects cotreatment	1
licochalcone B	increases expression	1
Decitabine	affects expression	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Cisplatin	affects expression	1
Dactinomycin	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Lead	affects expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Oxygen	increases expression	1
Phthalic Acids	increases methylation	1
Testosterone	increases expression	1
Tetrachlorodibenzodioxin	increases activity, affects reaction	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	decreases expression	1
Acrylamide	decreases expression	1
Particulate Matter	increases abundance, increases expression	1

ChEMBL screening assays

82 unique, capped per target: 82 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3632282	Binding	Inhibition of CAMK1beta (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity. — Bioorg Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TE75	HAP1 PNCK (-) 1	Cancer cell line	Male
CVCL_TE76	HAP1 PNCK (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.